<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02063568</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00051122</org_study_id>
    <nct_id>NCT02063568</nct_id>
  </id_info>
  <brief_title>The Use of Thromboelastometry (ROTEM) to Evaluate the Changes in Coagulation With Two Different Doses of Oxytocin Following Cesarean Delivery</brief_title>
  <official_title>The Use of Thromboelastometry (ROTEM) to Evaluate the Changes in Coagulation With Two Different Doses of Oxytocin Following Cesarean Delivery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Duke University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Duke University</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the differences in blood clotting seen in healthy
      patients given two different doses of oxytocin following cesarean delivery. The secondary
      objectives are to evaluate changes in blood pressure, rates of nausea and vomiting, and
      differences in blood loss with the two separate doses of oxytocin.
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <start_date>January 2015</start_date>
  <completion_date type="Actual">December 2015</completion_date>
  <primary_completion_date type="Actual">December 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>coagulation as assessed by ROTEM</measure>
    <time_frame>30 minutes after oxytocin infusion started</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>cardiac output changes with oxytocin</measure>
    <time_frame>from start of surgery until 30 min after oxytocin infusion started</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>incidence of nausea and vomiting with oxytocin</measure>
    <time_frame>from start of surgery until 30 minutes after oxytocin started</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>estimated blood loss with different doses of oxytocin</measure>
    <time_frame>upon completion of surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>changes in blood pressure with oxytocin</measure>
    <time_frame>from start of surgery until 30 minutes after oxytocin started</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Coagulation Changes With Oxytocin</condition>
  <arm_group>
    <arm_group_label>Low dose oxytocin infusion</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>oxytocin will be administered as an intravenous infusion at a rate of 0.33 units/min starting after fetal delivery upon umbilical cord clamping and continuing for a total of 30 minutes</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High dose oxytocin infusion</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>oxytocin will be administered as an intravenous infusion at a rate of 1.33 units/min starting after fetal delivery upon umbilical cord clamping and continuing for a total of 30 minutes</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxytocin</intervention_name>
    <arm_group_label>Low dose oxytocin infusion</arm_group_label>
    <arm_group_label>High dose oxytocin infusion</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  English speaking

          -  Age &gt; or = 18 yrs

          -  Non-laboring women

          -  cesarean delivery under spinal anesthesia with pfannenstiel incision

          -  ASA I-III

        Exclusion Criteria:

          -  Height &lt;5'0&quot;

          -  Allergy to phenylephrine

          -  Severe cardiac disease in pregnancy with marked functional limitations

          -  Women receiving NSAIDS, aspirin or other anticoagulants

          -  Subject enrollment in another study involving a study medication within 30 days of
             cesarean delivery

          -  Other physical or psychiatric condition which may impair the ability to cooperate with
             study data collection
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Duke University Hospital</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Solomon C, Collis RE, Collins PW. Haemostatic monitoring during postpartum haemorrhage and implications for management. Br J Anaesth. 2012 Dec;109(6):851-63. doi: 10.1093/bja/aes361. Epub 2012 Oct 16. Review.</citation>
    <PMID>23075633</PMID>
  </reference>
  <reference>
    <citation>George RB, McKeen D, Chaplin AC, McLeod L. Up-down determination of the ED(90) of oxytocin infusions for the prevention of postpartum uterine atony in parturients undergoing Cesarean delivery. Can J Anaesth. 2010 Jun;57(6):578-82. doi: 10.1007/s12630-010-9297-1. Epub 2010 Mar 18.</citation>
    <PMID>20238255</PMID>
  </reference>
  <reference>
    <citation>Balki M, Erik-Soussi M, Kingdom J, Carvalho JC. Oxytocin pretreatment attenuates oxytocin-induced contractions in human myometrium in vitro. Anesthesiology. 2013 Sep;119(3):552-61. doi: 10.1097/ALN.0b013e318297d347.</citation>
    <PMID>23676375</PMID>
  </reference>
  <reference>
    <citation>Tita AT, Szychowski JM, Rouse DJ, Bean CM, Chapman V, Nothern A, Figueroa D, Quinn R, Andrews WW, Hauth JC. Higher-dose oxytocin and hemorrhage after vaginal delivery: a randomized controlled trial. Obstet Gynecol. 2012 Feb;119(2 Pt 1):293-300. doi: 10.1097/AOG.0b013e318242da74.</citation>
    <PMID>22227638</PMID>
  </reference>
  <reference>
    <citation>Butwick A, Harter S. An in vitro investigation of the coagulation effects of exogenous oxytocin using thromboelastography in healthy parturients. Anesth Analg. 2011 Aug;113(2):323-6. doi: 10.1213/ANE.0b013e3182222a82. Epub 2011 Jun 3.</citation>
    <PMID>21642611</PMID>
  </reference>
  <reference>
    <citation>Neuenschwander S, Pliska V. Effects of neurohypophyseal hormone analogues on blood clotting factor VIII and fibrinolytic activity in sheep. Eur J Pharmacol. 1997 Apr 4;323(2-3):205-13.</citation>
    <PMID>9128840</PMID>
  </reference>
  <verification_date>October 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 12, 2014</study_first_submitted>
  <study_first_submitted_qc>February 12, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 14, 2014</study_first_posted>
  <last_update_submitted>December 14, 2015</last_update_submitted>
  <last_update_submitted_qc>December 14, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 16, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oxytocin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

